Alluvi Tirzepatide: Is It the Same Medicine as Mounjaro?

What Alluvi actually is, and why it shows up in UK searches

Alluvi is a brand name associated with compounded tirzepatide, prepared by compounding pharmacies primarily in the United States during periods when the licensed product was in short supply. Compounding involves mixing or repackaging a pharmaceutical substance outside of the manufacturer's standard production process. In the UK, compounding of a medicine that has an authorised equivalent is tightly restricted under the Human Medicines Regulations 2012, and tirzepatide compounded under the Alluvi name carries no MHRA marketing authorisation for the UK market.

The name circulates online partly because US-based telehealth providers marketed it widely, and partly because people researching tirzepatide for weight loss sometimes land on American content without realising it. That is a genuinely easy mistake. The regulatory landscape for medicines differs significantly between the US and the UK, so a product legally dispensed in one country may have no lawful status in the other.

The practical upshot: if a UK seller offers you something called Alluvi tirzepatide, it is not coming through the MHRA-authorised supply chain. That matters because the supply chain is where quality, concentration and sterility are verified. The MHRA has documented cases in which unlicensed injectable products contained the wrong substance entirely, including insulin in pens labelled as weight-loss medicines.

What the licensed UK alternative offers, and who it suits

Mounjaro is the licensed tirzepatide product for UK patients. It is available in a pre-filled KwikPen (each pen contains four weekly doses) across six strengths: 2.5, 5, 7.5, 10, 12.5 and 15mg. Treatment starts at the 2.5mg pen, which exists to let your system adjust gradually, and a prescriber steps doses upward at roughly four-week intervals based on how you are tolerating treatment and progressing, with patients who have already worked through earlier doses sometimes moving on to tirzepatide 30 as part of ongoing treatment discussion.

The clinical evidence behind tirzepatide is substantial. In the SURMOUNT-1 trial, involving around 2,500 adults with obesity, participants at the 15mg dose lost on average roughly 20–21% of their body weight over 72 weeks. That figure comes from the SURMOUNT-1 paper published in the New England Journal of Medicine, and NICE cited it when recommending tirzepatide in its guidance TA1026.

Private eligibility for Mounjaro broadly follows the licensed indication: adults with a BMI of 30 or above, or 27 and above alongside a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance. A prescriber looks at the whole picture, not just a number on a scale. You can get a clear sense of what the assessment covers by reading about weight-loss treatment options at nume.

The safety case for choosing a licensed, verifiable supply chain

For an injectable prescription medicine, the question of whether you are getting what the label says is not a theoretical concern. The MHRA seized approximately 20 million doses of illegally traded weight-loss medicines in 2025, worth an estimated £45 million, and raided a site in Northampton producing counterfeit tirzepatide pens. Fake pens have been found with incorrect concentrations or entirely wrong substances inside. None of those products could be returned, refunded or treated as evidence of harm without significant difficulty.

Legitimate supply looks very different. A GPhC-registered pharmacy sources directly from authorised UK distributors. Every step from manufacturer to patient is logged and inspected. You can verify any pharmacy's registration on the GPhC register before handing over any personal or payment details. At nume, our GPhC premises registration is 9012878, verifiable there directly.

When your order arrives, it comes in plain, unbranded packaging via DPD with a tracking number sent to your phone. Inside is a Mounjaro KwikPen from Eli Lilly's licensed UK supply, stored correctly through transit. That is the physical reality of a legitimate order. It is worth pausing on, because an unlicensed product arriving in similar-looking packaging offers no such chain of assurance.

If you want to understand how tirzepatide is priced through legitimate UK services, that page covers what drives cost variation and what a transparent private prescription actually includes. Separately, our clinical team page explains how prescriber oversight works at every stage.

What 'alluvi tirzepatide' searches suggest about what people actually need

When someone types this into a search engine, they are usually not looking for Alluvi specifically. They have heard about tirzepatide, perhaps from a friend or a news article, and this brand name appeared somewhere in their reading. What they actually want to know is whether tirzepatide is available to them, how much it costs, and whether an online pharmacy is a safe route.

Those are fair questions, and the answers are not complicated. Yes, tirzepatide is available in the UK as Mounjaro. Yes, a regulated online pharmacy can prescribe and dispense it legally. No, the process does not require a GP referral, a waiting list, or a clinic visit. A prescriber reviews your consultation the same day it is submitted. You can read more about the relationship between the Mounjaro brand and tirzepatide if that distinction still feels unclear, or explore the tirzepatide treatment overview for a fuller picture of what treatment involves.

If you are ready to find out whether Mounjaro is clinically suitable for you, a free consultation with a GPhC-registered prescriber is the right next step. Visit our weight-loss treatments page to begin.